College of Pharmacy, Western University of Health Sciences, 309 East Second Street, Pomona, CA, 91766, USA.
Patient. 2019 Dec;12(6):593-609. doi: 10.1007/s40271-019-00379-6.
A significant limitation of the traditional randomized controlled trials is that strong preferences for (or against) one treatment may influence outcomes and/or willingness to receive treatment. Several trial designs incorporating patient preference have been introduced to examine the effect of treatment preference separately from the effects of individual interventions. In the current study, we summarized results from studies using doubly randomized preference trial (DRPT) or fully randomized preference trial (FRPT) designs and examined the effect of treatment preference on clinical outcomes.
The current systematic review and meta-analysis was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Studies using DRPT or FRPT design were identified using electronic databases, including PubMed, Cochrane Library, EMBASE, and Google Scholar between January 1989 and November 2018. All studies included in this meta-analysis were examined to determine the extent to which giving patients their preferred treatment option influenced clinical outcomes. The following data were extracted from included studies: study characteristics, sample size, study duration, follow-up, patient characteristics, and clinical outcomes. We further appraised risk of bias for the included studies using the Cochrane Collaboration's risk of bias tool.
The search identified 374 potentially relevant articles, of which 27 clinical trials utilized a DRPT or FRPT design and were included in the final analysis. Overall, patients who were allocated to their preferred treatment intervention were more likely to achieve better clinical outcomes [effect size (ES) = 0.18, 95% confidence interval (CI) 0.10-0.26]. Subgroup analysis also found that mental health as well as pain and functional disorders moderated the preference effect (ES = 0.23, 95% CI 0.11-0.36, and ES = 0.09, 95% CI 0.03-0.15, respectively).
Matching patients to preferred interventions has previously been shown to promote outcomes such as satisfaction and treatment adherence. Our analysis of current evidence showed that allowing patients to choose their preferred treatment resulted in better clinical outcomes in mental health and pain than giving them a treatment that is not preferred. These results underline the importance of incorporating patient preference when making treatment decisions.
传统随机对照试验的一个显著局限性是,患者对(或反对)一种治疗方法的强烈偏好可能会影响治疗效果和/或接受治疗的意愿。为了单独研究治疗偏好的影响,引入了几种纳入患者偏好的试验设计。在本研究中,我们总结了使用双重随机偏好试验(DRPT)或完全随机偏好试验(FRPT)设计的研究结果,并研究了治疗偏好对临床结局的影响。
本系统评价和荟萃分析根据《系统评价和荟萃分析的首选报告项目》(PRISMA)指南进行。使用 DRPT 或 FRPT 设计的研究通过电子数据库(包括 PubMed、Cochrane Library、EMBASE 和 Google Scholar)进行检索,检索时间为 1989 年 1 月至 2018 年 11 月。对纳入的荟萃分析研究进行了评估,以确定给予患者首选治疗方案对临床结局的影响程度。从纳入的研究中提取了以下数据:研究特征、样本量、研究持续时间、随访、患者特征和临床结局。我们还使用 Cochrane 协作组的偏倚风险工具评估了纳入研究的偏倚风险。
检索共确定了 374 篇潜在相关文章,其中 27 项临床试验采用 DRPT 或 FRPT 设计,并纳入最终分析。总体而言,被分配到首选治疗干预的患者更有可能获得更好的临床结局[效应量(ES)=0.18,95%置信区间(CI)0.10-0.26]。亚组分析还发现,心理健康以及疼痛和功能障碍调节了偏好效应(ES=0.23,95%CI 0.11-0.36 和 ES=0.09,95%CI 0.03-0.15)。
先前的研究表明,让患者选择自己喜欢的干预措施可以促进满意度和治疗依从性等结局。我们对当前证据的分析表明,让患者选择自己喜欢的治疗方法比给予他们不喜欢的治疗方法更能改善心理健康和疼痛方面的临床结局。这些结果强调了在制定治疗决策时纳入患者偏好的重要性。